US FDA grants breakthrough therapy designation to Daiichi Sankyo & AstraZeneca’s Enhertu plus pertuzumab to treat unresectable or metastatic HER2 positive breast cancer Tokyo Friday, July 18, 2025, 14 ...

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends ...

Key companies developing therapies for Necrotizing Enterocolitis are - Abbott, Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson, and Company (BD), Bristol-Myers Squibb Company, Daiichi ...

The United States Food and Drug Administration (FDA) has granted breakthrough therapy designation to first-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) plus Perjeta (pertuzumab) for ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...